NeuroOne Medical Technologies Corporation
NMTC
$0.567
-$0.0126-2.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 153.37% | -6.87% | 20.22% | 18.95% | -93.03% |
| Total Depreciation and Amortization | 10.90% | 2.56% | 10.70% | 38.72% | 63.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -67.59% | 178.38% | 14.84% | 58.00% | 10.22% |
| Change in Net Operating Assets | -125.95% | -87.65% | -115.07% | 173.38% | 59.05% |
| Cash from Operations | 105.46% | 8.13% | 19.72% | 38.75% | -9.08% |
| Capital Expenditure | 34.23% | 35.94% | 89.38% | 82.13% | -222.61% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 34.23% | 26.35% | -101.72% | -101.72% | -345.70% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -86.14% | 3.63% | 125.60% | -- |
| Repurchase of Common Stock | 16.91% | -13.95% | -282.79% | 88.55% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,221.22% | 305.15% | -48.25% | 26.79% | -140.13% |
| Cash from Financing | -142.27% | -51.00% | -0.02% | 196.10% | 7,775.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 87.67% | -107.14% | -57.07% | 76.88% | 24.38% |